Dr. Lori Hazlehurst, a professor at the West Virginia University School of Pharmacy, is being recognized for her expertise in cancer research. She was recently appointed associate director for translational
research on the WVU Cancer Institute’s (WVUCI) Scientific Research Team. The appointment is part of a broader leadership realignment aimed at advancing the institute’s pursuit of National Cancer Institute (NCI) designation. Executive Chair and Director of the WVUCI, Dr. Hannah Hazard-Jenkins also appointed Dr. Ashkan Emadi as associate director for clinical research and Dr. Reagan Curtis as associate director for cancer research training and education coordination. Dr. Stephenie Kennedy-Rea will continue to serve as associate director for community outreach and engagement.
“Filling these essential roles with such remarkable talents marks a significant step forward toward building the infrastructure necessary to run a clinical, research, and educational enterprise worthy of National Cancer Institute (NCI) designation – the only in West Virginia,” said Hazard-Jenkins.
NCI-designated cancer centers are recognized as national leaders in cancer treatment, research and education. To earn the designation, a center must undergo a rigorous evaluation process and meet specific criteria. Currently, there are 73 NCI-designated cancer centers across 37 states and the District of Columbia.